Don’t miss the latest developments in business and finance.

USFDA completes inspection of Biocon's Bengaluru plant with no observations

Image
Press Trust of India New Delhi
Last Updated : Nov 12 2018 | 10:35 AM IST

Biotechnology major Biocon Monday said the US health regulator has completed inspection of its new manufacturing facility in Bengaluru without any observations.

"The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection of our new oral solid dosage forms manufacturing facility at Biocon Park in Bengaluru from November 5-9, 2018," Biocon said in a regulatory filing.

The audit concluded without any observations and no Form 483 was issued, the company added.

A Form 483, is issued by the USFDA to notify a company's management of any objectionable conditions at its manufacturing facilities. It is issued to the management of a firm at the conclusion of an inspection.

Shares of Biocon were trading 0.27 per cent lower at Rs 638.70 apiece on BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Nov 12 2018 | 10:35 AM IST

Next Story